{"filing":{"accession_number":"0001856725-26-000003","cik":"0001856725","ticker":"RANI","company_name":"Rani Therapeutics Holdings, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"rani-20260624.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1856725/000185672526000003/rani-20260624.htm"},"events":[{"id":14774,"run_id":13162,"accession_number":"0001856725-26-000003","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Nicholas M. Maestas as Chief Financial Officer (principal financial officer and principal accounting officer) effective June 29, 2026, succeeding Svai Sanford. While the section also includes compensatory details (base salary of $500,000, 75% bonus target, and a 2,000,000-share option grant), the principal disclosed action is the appointment of a named executive to a principal officer role, making exec_appointment the most salient classification. The appointment of a CFO is material to investors as it affects the registrant's financial leadership and governance.","company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12311,"accession_number":"0001856725-26-000003","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Nicholas M. Maestas as Chief Financial Officer (principal financial officer and principal accounting officer) effective June 29, 2026, succeeding Svai Sanford. While the section also includes compensatory details (base salary of $500,000, 75% bonus target, and a 2,000,000-share option grant), the principal disclosed action is the appointment of a named executive to a principal officer role, making exec_appointment the most salient classification. The appointment of a CFO is material to investors as it affects the registrant's financial leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T10:03:03.791964+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12311,"accession_number":"0001856725-26-000003","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Nicholas M. Maestas as Chief Financial Officer (principal financial officer and principal accounting officer) effective June 29, 2026, succeeding Svai Sanford. While the section also includes compensatory details (base salary of $500,000, 75% bonus target, and a 2,000,000-share option grant), the principal disclosed action is the appointment of a named executive to a principal officer role, making exec_appointment the most salient classification. The appointment of a CFO is material to investors as it affects the registrant's financial leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T10:03:03.791964+00:00","company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","filing_date":"2026-06-29"}]}